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A B S T R A C T
Curcuminoids (curcumin, demethoxycurcumin and bis-demethoxycurcumin) are poorly ab-
sorbed and rapidly metabolised and excreted. We investigated in healthy young and aged
women and men if co-administration of adjuvants (sesamin, ferulic acid, naringenin, and
xanthohumol) alone or in combination withmicellar solubilisation improves the bioavailability
of curcuminoids. A single oral dose of 98 mg curcuminoids was administered as native
curcuminoids (NC), native curcuminoids plus phytochemicals (NCP), curcuminoid micelles
(MC) or curcuminoid plus phytochemical micelles (MCP). Total curcuminoids were quanti-
fied in blood samples collected over 24 h. Based on the area under the curve, NCP, MC, and
MCP increased the bioavailability of the major curcuminoid curcumin 8-, 88-, and 73-fold,
respectively, compared to NC. No sex or age differences were observed. Thus, simultane-
ous ingestion of phytochemicals does modestly increase curcuminoid bioavailability, but
does not enhance the large increase in bioavailability observed with micellar curcuminoids.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Curcuminoids are lipophilic polyphenols present in the rhizome
of the plant turmeric (Curcuma longa Linn.). Dried and ground
turmeric contains 3–5% curcuminoids of which curcumin
makes up ca. 75–80%, demethoxycurcumin (DMC) 15–20% and
bis-demethoxycurcumin (BDMC) 4–8% (all by weight) (Anand,
Kunnumakkara, Newman, & Aggarwal, 2007). In addition to its
use as a food additive (E100) and spice, curcumin possesses
numerous health beneficial effects and has been tradition-
ally used in Ayurvedic medicine for the treatment of respiratory
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and liver disorders, anorexia, rheumatism, diabetic wounds,
runny nose, cough and sinusitis (Araujo & Leon, 2001). In cell
culture, animal and human studies, curcuminoids exert anti-
carcinogenic, anti-inflammatory and antioxidative activities
(Goel, Kunnumakkara, & Aggarwal, 2008) and may therefore
be useful in the prevention and treatment of disorders such
as cancer, arteriosclerosis, diabetes mellitus and Alzheimer’s
disease (Aggarwal & Sung, 2009).
The oral bioavailability of curcuminoids,however, is low.Due
to their hydrophobicity and thus poor solubility in the chyme
as well as their instability at physiological and alkaline pH
(Wanget al., 1997),only a small fractionof ingested curcuminoids
is absorbed. In the intestine and liver, curcuminoids undergo
rapid metabolism by reductases to di-, tetra-, hexa- and
octahydrocurcuminoids. The reduced metabolites are conju-
gated predominantlywith glucuronic acid and to a lesser extent
sulphate to hydrophilic derivatives that facilitate their biliary
and urinary excretion (Hoehle, Pfeiffer, &Metzler, 2007; Hoehle,
Pfeiffer, Solyom, & Metzler, 2006; Ireson et al., 2002). The
bioavailability of curcuminoids is further limited by the activ-
ity of transport proteins in the luminalmembrane of enterocytes
that transfer the intracellular conjugates back to the intesti-
nal lumen. In rats andhumans,only negligible amounts of orally
ingested curcumin are excreted as urinarymetabolites (Schiborr
et al., 2014; Wahlström& Blennow, 1978), while themajority is
eliminatedunchangedwith faeces (Wahlström&Blennow, 1978).
Different strategies to increase the uptake and systemic avail-
ability of curcumin and consequently its biological activity have
been investigated.One such strategy is the inhibitionof curcumin
metabolism with adjuvants that interfere with metabolising
enzymes. In eight healthy human volunteers, the concomi-
tant ingestion of curcumin (2 g) and piperine (20 mg) resulted
in a 20-fold higher area under the plasma concentration–time
curve (AUC) in comparison with curcumin alone (Shoba et al.,
1998).
Other phytochemicals may also have the potential to alter
curcuminoid metabolism and bioavailability. For example,
ferulic acid, because of its structural similarity with curcumin
(also known as diferuloylmethane), might competitively inhibit
xenobiotic enzymes involved in the biotransformation of
curcuminoids. Naringenin inhibits phase II enzymes, such as
the UDP-glucuronosyltransferase (UGT) 1A1, conjugating
curcuminoids with glucuronic acid (Williams et al., 2002) and
membrane transporters exporting glucuronidated metabo-
lites out of intestinal cells (Brand et al., 2006). Sesamin is
metabolised by and modulates the activities of phase I and II
enzymes, including UGT and catechol-O-methyltransferases
(Yasuda et al., 2011), and in our previous animal and human
studies significantly inhibited the metabolism and pharma-
cokinetics of vitamin E (Frank et al., 2006, 2008; Grebenstein,
Schumacher, Graeve, & Frank, 2014; Kamal-Eldin et al., 2000;
Ross et al., 2004). Xanthohumol is conjugated by UGT and
sulphotransferases (Ruefer, Gerhauser, Frank, Becker, & Kulling,
2005) and might thus competitively inhibit the metabolism of
curcuminoids by these enzymes.
Another frequently employed strategy is the administra-
tion of curcumin in the form of novel delivery systems, such
as nanoparticles, liposomes, or micelles, designed to enhance
its solubility and stability in the gastrointestinal tract (Kurita &
Makino, 2013). The hitherto largest increase in curcumin
bioavailability reported in the literaturewas achievedwith 410mg
micellar curcumin in our recent human trial involving 23 healthy
subjects, in which 185-fold larger AUC and a 455-fold higher
maximum total curcumin plasma concentration (Cmax) were
observed (Schiborr et al., 2014).
In the present trial, we therefore aimed to investigate if
the combination of the two strategies “co-administration of
adjuvants” and “micellar solubilisation” results in synergistic
enhancement of the bioavailability of curcuminoids.To this end,
native or micellar curcuminoids were administered simulta-
neously with or without a mixture of the adjuvants sesamin,
naringenin, ferulic acid, and xanthohumol, in a single-blind,
crossover, human study and their pharmacokinetics followed
for 24 h.The sex and age differences in the pharmacokinetics
and the safety of these strategies were further examined. Both
strategies, if successful,may enhance the health-beneficial po-
tential of curcuminoids and thus spur their use as ingredients
in dietary supplements and functional foods.
2. Materials and methods
2.1. Curcumin formulations
The native curcumin powder used for the preparation of all
formulationswas from Jupiter Leys (Cochin, Kerala State, India)
and contained 82% curcumin, 16% demethoxycurcumin (DMC),
and 2% bis-demethoxycurcumin (BDMC). The phytochemical
mixture (formulations containing adjuvants) contained
curcumin, sesamin (99%pure,CAS # 607-80-7), ferulic acid (≥98%
pure, CAS # 1135-24-6), naringenin (≥98% pure, CAS # 480-41-1)
from Intatrade Chemicals GmbH (Friedersdorf, Germany), and
xanthohumol (>85%pure,CAS#6754-58-1) fromSimonH.Steiner
Hopfen GmbH (Mainburg, Germany) in the ratio 2:2:1:1:1 (by
weight). Silicon dioxide was used as filler in the preparations
withnative curcumin.Themicelles consisted of 7% curcuminoid
powder (equal to 6% curcumin) and 93% Tween-80 (Kolb,
Hedingen, Switzerland) and were produced by AQUANOVAAG
(Darmstadt, Germany). Micelles with phytochemicals con-
sisted of 95.1% Tween-80, 1.4% curcumin, 1.4% sesamin, and
0.7% naringenin, 0.7% ferulic acid and 0.7% xanthohumol.The
single dose administered with each of the formulations was
98mg total curcuminoids and80.36 mgcurcumin,15.68 mgDMC
and 1.96 mg BDMC. Placebo capsules (see 2.2) contained mi-
celles composed of 7%medium-chain triacylglycerols and 93%
Tween-80 (AQUANOVA). All (powder and liquid) formulations
were filled into LiCaps® capsules (Capsugel France SAS, Colmar
Cedex, France).
2.2. Subjects and study design
The study protocol was reviewed and approved by the ethics
committee of the State Medical Society of Baden-Württemberg
(Germany) and the trial registered (NCT01982734) at
ClinicalTrials.gov. Exclusion criteria included use of medica-
tions (with exception of contraceptives), pregnancy, lactation,
chronic diseases, drug or alcohol abuse, smoking, use of dietary
supplements, >5 h physical activity per week, or hypersensi-
tivity to curcuminoids. Twenty-three healthy human subjects
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aged 18–35 years (6 women, 6 men) or >60 years (5 women, 6
men) with normal liver and kidney function parameters were
recruited and gave written informed consent for this
randomised, single-blind, crossover trial. The subjects were
asked to avoid curcumin-containing foods starting one week
before the first intervention and throughout the entire study.
Subjects fasted for 12 h prior to the first blood draw on each
of the intervention days and received in random order 10 cap-
sules equivalent to a single oral dose of 98 mg curcuminoids
in the form of native curcuminoids (NC), native curcuminoids
plus phytochemicals (NCP), micellar curcuminoids (MC) or
micellar curcuminoids plus phytochemicals (MCP). Due to the
higher curcumin loading of the MC compared to the MCP
micelles, subjects in the MC group were given 8 placebo and
2 curcuminoid capsules. All capsules were taken with water
within 5 min. The four intervention arms were separated by
one-week washout periods. In order to control for the influ-
ence of the diet on curcuminoid pharmacokinetics, subjects
received standardisedmeals starting with dinner on the evening
before and during the entire intervention day (see Schiborr et al.,
2014 for details). Blood was collected 0, 0.5, 1, 2, 4, 6, 8 and 24 h
after intake of capsules and safety parameters determined in
samples taken at 0, 4 and 24 h. Urine was sampled for 24 h
starting with the second bladder emptying on the morning
of the intervention. Urine containers contained 30 mL 10%
phosphoric acid solution and were replaced by fresh ones just
prior to (0 h) and 6 and 12 h after curcuminoid intake.
2.3. Sample preparation and determination of
safety parameters
EDTA plasma was prepared immediately by centrifugation
(1008 × g, 10 min, 4 °C) and stored at −80 °C.Serumsampleswere
left at roomtemperature for 30min,centrifuged (1008 × g, 15 min,
20 °C), and stored at −80 °C or immediately sent to the clinical
laboratory Laborärzte Sindelfingen (Sindelfingen, Germany)
for quantification of safety parameters. Urine was weighed,
aliquoted, and stored at −80 °C until further analysed.
2.4. HPLC analysis of curcumin, DMC and BDMC
Samples were extracted using a modified method of Heath,
Pruitt, Brenner, and Rock (2003), Schiborr, Eckert, Rimbach, and
Frank (2010), and Schiborr et al. (2014). One millilitre of EDTA
(ethylenediamine tetraacetic acid) plasma and 10 µL 6 M hy-
drochloric acid were transferred into a glass tube. Urine samples
were adjusted with 6 M hydrochloric acid or 6 M sodium hy-
droxide to pH 4.0–4.5 and 1 mL transferred to a fresh glass tube.
One-hundred microlitres β-glucuronidase type H1 from Helix
Pomatia (1 mg/100 mL in 0.1 M sodium acetate buffer; Sigma-
Aldrich Chemie GmbH, Schnelldorf, Germany) were added to
each plasma or urine sample, which were then incubated for
45 min at 37 °C.Then 3mL extraction solvent (95% ethyl acetate
and 5% methanol (v/v)) was added, vortex-mixed for 30 s and
centrifuged (1008 × g, 5 min, 4 °C). The supernatants were
collected in clean glass tubes. The extraction procedure was
repeated twice. The pooled supernatants were evaporated to
dryness using a RVC 2–25 CDplus centrifugal evaporator (Martin
Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz,
Germany). The dried residues were re-suspended in 150 µL
methanol, vortex-mixed for 30 s, kept for 10 min in the dark,
vortex-mixed for 20 s and transferred to HPLC sample vials.
Twenty microlitres of each sample were injected into a Jasco
HPLC system (Jasco GmbH, Gross-Umstadt, Germany) equipped
with a Reprosil-Pur C18-AQ column (150 × 4 mm; 3 µm par-
ticle size; Dr. Maisch GmbH,Ammerbuch, Germany) maintained
at 40 °C. The mobile phase (52% de-ionised water adjusted to
pH 3 with perchloric acid, 34% acetonitrile and 14% metha-
nol; all by volume) was delivered at a flow rate of 1.4 mL/
min. Curcuminoids were quantified by fluorescence detection
(excitation wavelength, 426 nm; emission wavelength, 536 nm)
using external standards (curcumin, purity ≥97.2%, CAS # 458-
37-7; DMC, purity ≥98.3%, CAS # 22608-11-13; and BDMC, purity
≥99.4%, CAS # 24949-16-0; all from Chromadex, Irvine, CA, USA).
The limits of detection (LOD) of our method were curcumin,
13.6; DMC, 14.8, and BDMC, 1.6 nmol/L, respectively and the re-
spective lower limits of quantification (LLOQ) were curcumin,
27.1; DMC, 29.6, and BDMC, 3.2 nmol/L, respectively.The mean
values reported in the tables are in some cases lower than
the LLOQ because many samples following the ingestion of
the native curcuminoids were below the LLOQ, while some
contained higher and quantifiable amounts of curcuminoids.
2.5. Statistical analyses
AUC was calculated using the trapezoidal rule and Tmax was
estimated by visual inspection of the graphs. Statistical dif-
ferences between treatments were analysed by repeated-
measures one-way ANOVAwith a Bonferroni post-test or, when
data were not normally distributed, by the Friedman test with
Dunn’s post-test. Age and sex differences within each inter-
vention group were compared by one-way ANOVA with
Bonferroni post-test, or, when not normally distributed, with
Dunn’s post-test. A p-value of <0.05 was considered signifi-
cant. GraphPad Prism version 5.00 for Windows was used for
all statistical analyses (GraphPad Software, San Diego, CA, USA).
Reported values are arithmetic means with SD or SEM, as
indicated.
3. Results
3.1. Baseline characteristics, safety, and adverse events
Eleven women (young, 23 ± 2 years, n = 6; aged, 67 ± 3 years,
n = 5) and twelve men (young, 26 ± 2 years, n = 6; aged, 62 ± 3,
n = 6) took part in the study. Men and women differed
significantly in height but not in weight or BMI (Table 1). Total
cholesterol concentrations were significantly higher in old
women than in young men and LDL cholesterol was higher in
old women than young women and men. HDL cholesterol,
triacylglycerol (TAG) and fasting plasma glucose concentra-
tions were similar in all groups.
Liver and kidney function markers were measured 0, 4 and
24 hours after curcuminoid intake. Significant differences
between groups and formulations were observed, but, apart
from bilirubin (men young and aged), cholesterol (women and
men aged), LDL cholesterol (men aged) and cystatin C (men
aged), stayed within the reference ranges (Supplementary data).
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Adverse events recorded after curcumin ingestion were: in-
creased stool frequency (not diarrhoea; 1 subject, NC), tiredness
(1 subject, NC; 4 subjects, MC), headache (2 subjects, NC; 4 sub-
jects,MC), cardialgia (1 subject, NC; 2 subjects,MC), regurgitation
(1 subject, NCP) and nausea (1 subject, MC).
3.2. Plasma and urine concentrations of curcumin, DMC
and BDMC
Baseline samples of plasma and urine did not contain curcumin,
DMC or BDMC.The oral bioavailability of curcumin was 8-fold,
88-fold and 73-fold improved after intake of NCP, MC and MCP
in comparison to NC (calculation based on the AUC). Based
on Cmax, the increase of curcumin plasma concentrations was
7- (NCP), 216- (MC) and 175-fold (MCP) relative to NC (Fig. 1,
Table 2). Curcumin Cmax were reached 8 h after ingestion of
NC and NCP, and 1 hour after consumption of the micellar for-
mulations. DMC plasma concentrations increased 125-fold
(NCP), 848-fold (MC) and 597-fold (MCP) and BDMC concentra-
tions 54-fold (NCP), 159-fold (MC) and 110-fold compared with
NC (calculation based on the AUC). No sex and age differ-
ences in the plasma concentrations of curcuminoids were
observed.
Urinary excretion of curcumin, DMC and BDMC was sig-
nificantly higher after ingestion of the micellar than the native
curcuminoid formulations (Table 3). After consumption of NCP,
the urinary excretion of BDMCwas significantly higher in young
women than young men and the aged subjects.
4. Discussion
Curcuminoids, and particularly the predominant curcuminoid
curcumin, are promising nutraceuticals for the prevention and
treatment of a number of diseases (Esatbeyoglu et al., 2012).
Since quantifiable curcumin plasma concentrations in studies
using native curcumin are only achieved with gram doses
(Cheng et al., 2001; Lao et al., 2006; Vareed et al., 2008),
researchers are developing strategies to enhance its oral
bioavailability in order to optimise its biological activities. To
date, several such strategies have been investigated in phar-
macokinetic trials (Antony et al., 2008; Cuomo et al., 2011; Gota
et al., 2010; Jager et al., 2014; Kanai et al., 2012; Krishnakumar,
Ravi, Kumar, Kuttan, & Maliakel, 2012; Pawar et al., 2012; Sasaki
et al., 2011; Schiborr et al., 2014; Shoba et al., 1998).These studies
and therefore the efficacies of the developed strategies are
difficult to compare with each other, because the analytical
methods for the quantification of curcumin differed (some labo-
ratories measured free, others total curcumin after hydrolysis
of conjugates), different doses of curcumin were used in the
native and the novel formulations (see below for details why
this is not appropriate), and many studies were not suffi-
ciently controlled to exclude that differences in food intakemay
have affected curcumin pharmacokinetics (Antony et al., 2008;
Cuomo et al., 2011; Gota et al., 2010; Jager et al., 2014; Kanai
et al., 2012; Krishnakumar et al., 2012; Pawar et al., 2012; Sasaki
et al., 2011; Shoba et al., 1998).
One strategy to increase plasma concentrations of
curcuminoids is the concomitant application of adjuvants to
inhibit their metabolism and elimination (Shoba et al., 1998).
In our trial, the simultaneous ingestion of native curcumin with
phytochemicals increased the AUC for total curcumin 8-fold
in comparison to native curcumin alone. In agreement, in 11
subjects receiving 2 g curcumin alone or in combination with
turmeric essential oils (BCM-95®CG), the AUC of curcumin was
increased 7-fold (Antony et al., 2008). The simultaneous ap-
plication of 2 g curcumin with 20 mg piperine (n = 8) in another
study increased the AUC of free curcumin 20-fold compared
to native control (Shoba et al., 1998).
Our micellar curcuminoid formulation increased the AUC
of curcumin, DMC and BDMC 88-, 848- and 159-fold relative
to the native formulation, with Cmax of 130, 58 and 3 nmol/L,
respectively (Table 2). In our previous pharmacokinetic study
with a single oral dose of 500 mg curcuminoids (410 mg
curcumin), we observed 185-, 141-, and 12-fold higher total
curcumin, DMC, and BDMC AUC, respectively, with micellar
compared to native curcuminoids.Total curcumin Cmax in that
study was 3228 nmol/L for the micellar formulation (Schiborr
et al., 2014).Thus, the fold-bioavailability of the micellar (but also
the native) formulation is clearly affected by the adminis-
tered dose and cannot be extrapolated to lower or higher doses
of the formulation and not even from one curcuminoid to the
other. In another human study, a single oral dose of 30 mg
curcumin formulated as colloidal nanoparticle dispersion
(“Theracurmin”) resulted in a 27-fold larger total curcumin AUC
relative to native curcumin and a Cmax of 80 nmol/L (Sasaki et al.,
2011).
Table 1 – Baseline characteristics (mean ± SD) of the subjects (healthy young and aged women and men) at screening
grouped by sex and age.1
Variable Young women (n = 6) Aged women (n = 5) Young men (n = 6) Aged men (n = 6) P <
Age [y] 23 ± 2a 67 ± 3b 26 ± 2a 62 ± 3c 0.01
Body height [m] 1.68 ± 0.04a 1.61 ± 0.1a 1.86 ± 0.04b 1.80 ± 0.06b 0.01
Body weight [kg] 60.1 ± 3.9a 67.8 ± 17.6a,b 76.3 ± 6.6a,b 78.0 ± 10.4b 0.05
BMI [kg/m2] 21.4 ± 1.2 25.8 ± 5.4 22.1 ± 1.4 24.4 ± 2.4 ns
Total cholesterol [mg/dL] 186.3 ± 31.1a,b 234.4 ± 35.6b 175.2 ± 14.9a 211.2 ± 26.0a,b 0.05
LDL cholesterol [mg/dL] 110.5 ± 24.5a 158.4 ± 29.1b 112.5 ± 10.7a 143.3 ± 17.3a,b 0.05
HDL cholesterol [mg/dL] 67.8 ± 11.7 61.0 ± 10.3 58.3 ± 9.8 57.2 ± 12.1 ns
Triacylglycerols [mg/dL] 80.5 ± 31.6 96.4 ± 23.6 101.8 ± 38.4 79.3 ± 19.1 ns
Fasting plasma glucose [mg/dL] 83.5 ± 8.5 91.8 ± 12.2 89.2 ± 7.9 93.5 ± 8.0 ns
1 Statistical differences between groups were calculated by one-way ANOVA.
Values within a line not sharing a common lowercase letter are significantly different at the given P-value.
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As mentioned above, it is only possible to compare the
bioavailability of different formulations of the same com-
pound if it is administered at identical doses, which is a
prerequisite not always fulfilled by published studies of
curcumin pharmacokinetics. Hence, it is not possible to cal-
culate the fold-bioavailability relative to native curcumin for these
studies (Cuomo et al., 2011; Gota et al., 2010; Jager et al., 2014;
Krishnakumar et al., 2012). It is possible, however, to compare
the Cmax achieved with different doses of curcumin adminis-
tered with the different novel formulations to give a rough
estimate of their efficacies, even though Cmax does not take
into account the elimination kinetics and is thus a less robust
predictor of the amount of curcumin that may be available for
biological activity over a given period of time (typically 24 h).
In a dose-escalation study with 150 and 210 mgTheracurmin,
total curcumin Cmax of 513 and 747 nmol/L, respectively, were
observed (Kanai et al., 2012). The intake of 297 mg curcumin
as part of a lecithin formulation (Meriva) resulted in a Cmax of
137 nmol/L total curcumin (Cuomo et al., 2011). Interestingly,
plasma concentrations of DMCwere higher than curcumin con-
centrations, although the natural curcuminoid powder
contained about 4 times more curcumin (Cuomo et al., 2011).
Total curcumin Cmax following the oral administration of
376 mg curcuminoids in a curcumin phytosome formulation,
Fig. 1 – Mean (±SEM) total plasma concentrations [nmol/L] of curcumin, demethoxycurcumin (DMC) and bis-
demethoxycurcumin (BDMC) administered in a crossover design to healthy women and men as a single oral dose of
capsules containing 98 mg curcuminoids (n = 23) in the form of native curcumin (NC), native curcumin plus phytochemicals
(sesamin, ferulic acid, naringenin, xanthohumol; NCP), micellar curcumin (MC) or micellar curcumin plus phytochemicals
(MCP). Please observe the significant differences in the scales of the graphs for native and micellar curcumin.
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Table 2 – Pharmacokinetic parameters (mean ± SD) of curcumin, DMC and BDMC in healthy young and aged women and
men after a single oral dose of 98 mg curcuminoids in the form of native curcumin (NC), native curcumin plus
phytochemicals (sesamin, ferulic acid, naringenin, xanthohumol; NCP), micellar curcumin (MC) or micellar curcumin
plus phytochemicals (MCP).1,2,3
Curcumin NC NCP MC MCP P <
AUC [nmol/L·h]
All (n = 23) 6.5 ± 12.2a 49.6 ± 31.4a 574.7 ± 144.3b 475.9 ± 204.8b 0.01
Women young (n = 6) 6.9 ± 11.4a 44.8 ± 21.4a 576.8 ± 207.3b 508.6 ± 169.8b 0.001
Women aged (n = 5) 0.2 ± 0.5a 46.4 ± 46.3a 612.7 ± 163.5b 403.1 ± 89.5b 0.01
Men young (n = 6) 11.2 ± 19.1a 45.1 ± 34.2a 524.2 ± 121.1b 362.0 ± 145.6c 0.01
Men aged (n = 6) 2.3 ± 3.2 a 61.7 ± 27.8a 591.6 ± 88.1b 617.9 ± 286.1b 0.001
Cmax [nmol/L]
All (n = 23) 0.6 ± 1.3a 3.9 ± 2.3a 129.7 ± 61.4b 104.9 ± 59.6b 0.01
Women young (n = 6) 0.6 ± 1.5a 4.3 ± 2.8a 121.9 ± 58.75b 95.47 ± 23.0b 0.001
Women aged (n = 5) 0.5 ± 1.2a 3.4 ± 3.8a 173.1 ± 81.9b 147.8 ± 86.0b 0.01
Men young (n = 6) 1.1 ± 2.1a 4.6 ± 1.8a 109.2 ± 43.1b 71.8 ± 40.4b 0.05
Men aged (n = 6) 0.9 ± 1.3a 4.9 ± 1.8a 118.7 ± 54.6b 106.1 ± 64.3b 0.01
Tmax [h]
All (n = 23) 8.0 8.0 1.0 1.0
Women young (n = 6) 4.0 6.0 1.0 1.0
Women aged (n = 5) 8.0 8.0 1.0 1.0
Men young (n = 6) 8.0 8.0 1.0 1.0
Men aged (n = 6) 2.0 6.0 1.0 1.0
DMC NC NCP MC MCP P <
AUC [nmol/L·h]
All (n = 23) 0.2 ± 0.5a 24.9 ± 14.4a 169.5 ± 57.8b 119.4 ± 43.5b 0.05
Women young (n = 6) 0.1 ± 0.2a 22.5 ± 8.5a 165.0 ± 73.5b 127.9 ± 47.6b 0.01
Women aged (n = 5) 0.2 ± 0.5a 23.9 ± 20.8a 186.2 ± 49.8b 119.2 ± 17.9c 0.05
Men young (n = 6) 0.2 ± 0.4a 23.6 ± 17.1a 129.3 ± 35.2b 88.1 ± 26.6c 0.01
Men aged (n = 6) 0.5 ± 0.7a 29.5 ± 13.0a 200.4 ± 51.7b 142.4 ± 56.7c 0.05
Cmax [nmol/L]
All (n = 23) 0.3 ± 0.6a 2.2 ± 2.5a 57.7 ± 24.5b 39.5 ± 18.4b 0.01
Women young (n = 6) 0.1 ± 0.2a 2.7 ± 1.3a 57.8 ± 35.5b 36.5 ± 10.5b 0.05
Women aged (n = 5) 0.3 ± 0.6a 2.6 ± 3.5a,b 66.5 ± 50.6c 56.1 ± 19.4b,c 0.05
Men young (n = 6) 0.2 ± 0.6a 1.8 ± 0.9a 42.9 ± 13.5b 26.3 ± 6.6c 0.05
Men aged (n = 6) 0.5 ± 0.9a 3.3 ± 1.9a 63.0 ± 25.6b 39.8 ± 22.6b 0.01
Tmax [h]
All (n = 23) 1.0 2.0 1.0 1.0
Women young (n = 6) 1.0 6.0 1.0 1.0
Women aged (n = 5) 1.0 2.0 0.5 1.0
Men young (n = 6) 1.0 8.0 1.0 1.0
Men aged (n = 6) 1.0 2.0 1.0 1.0
BDMC NC NCP MC MCP P <
AUC [nmol/L·h]
All (n = 23) 0.08 ± 0.18a 4.3 ± 1.9b 12.7 ± 3.8c 8.8 ± 4.1c 0.05
Women young (n = 6) 0.02 ± 0.04a 3.7 ± 1.2b 12.6 ± 3.5c 9.6 ± 2.1c 0.05
Women aged (n = 5) 0.04 ± 0.06a 3.9 ± 2.3b 15.0 ± 2.2c 7.5 ± 1.3b 0.05
Men young (n = 6) 0.14 ± 0.29a 4.8 ± 2.2b 11.0 ± 4.2c 6.2 ± 2.5b 0.05
Men aged (n = 6) 0.13 ± 0.19a 4.7 ± 2.2a 12.4 ± 4.6b 11.8 ± 6.3b 0.05
Cmax [nmol/L]
All (n = 23) 0.04 ± 0.06a 0.5 ± 0.4b 3.4 ± 2.2c 2.0 ± 1.1c 0.05
Women young (n = 6) 0.02 ± 0.03a 0.4 ± 0.2a 3.0 ± 1.2b 2.0 ± 1.2b 0.05
Women aged (n = 5) 0.05 ± 0.08a 0.4 ± 0.3a,b 4.7 ± 2.7c 3.1 ± 1.3c,b 0.05
Men young (n = 6) 0.05 ± 0.08a 0.4 ± 0.1a 3.5 ± 2.9b 1.4 ± 0.5b 0.05
Men aged (n = 6) 0.05 ± 0.07a 0.7 ± 0.4a,b 2.8 ± 1.7b 2.1 ± 1.2a,b 0.05
Tmax [h]
All (n = 23) 1.0 2.0 1.0 1.0
Women young (n = 6) 1.0 2.0 1.0 1.0
Women aged (n = 5) 1.0 2.0 1.0 1.0
Men young (n = 6) 1.0 8.0 1.0 1.0
Men aged (n = 6) 1.0 2.0 1.0 2.0
1 AUC, area under the plasma concentration time curve; Cmax, maximum plasma concentration; Tmax, time to reach maximum concentration.
2 Repeated-measure, one-way ANOVA was performed using GraphPad Prism version 5.00 forWindows (GraphPad Software, San Diego, CA, USA)
to analyse differences between formulations. Values within a line not sharing a common lowercase letter are significantly different at the
given P-value.
3 No sex and age differences could be detected (one-way ANOVA was performed using GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA, USA) to analyse differences between groups).
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a formulation with volatile oils of turmeric rhizome, and a for-
mulation consisting of a hydrophilic carrier, cellulose derivatives,
and natural antioxidants were 8, 1, and 74 nmol/L, respec-
tively. Native curcumin was administered at a single dose of
1.8 g and reached a Cmax of 6 nmol/L (Jager et al., 2014). Cmax
of 61 nmol/L curcumin were observed following the inges-
tion of 130–195 mg curcumin as solid lipid particles (Longvida),
whereas a single dose of >390mg native curcumin did not result
in detectable curcumin in 6 healthy men (Gota et al., 2010). Cmax
of 60, 787, and 1004 nmol/L curcumin were reported for single
oral doses of 1 g native curcumin or 100 or 600 mg curcumin
administered as a dispersion of curcumin-impregnated soluble
dietary fibre (Krishnakumar et al., 2012). Cmax of 498 nmol/L
was reached with a single oral dose of 750 mg curcumin from
a lipid-based formulation in healthy humans (Pawar et al.,
2012).
In the present trial, co-ingestion ofmicellar phytochemicals
(MCP) resulted in a 73-fold larger curcumin AUC relative to the
native compound and did not synergistically increase curcumin
bioavailability over that observed with the micellar formula-
tionalone (MCP,88-fold largerAUC thannative curcumin;Table 2).
The bioavailability-enhancing effect of micellar solubilisation
appears to be much larger than that of the co-administration
of phytochemicals. Thus, even though the adjuvants may
moderately elevate plasma concentrations of curcumin, their
use should be carefully weighed against the risk of altered
pharmacokinetics and pharmacodynamics of drugs because of
their ability to influence theactivityofdrugmetabolisingenzymes
and transporters (Rodriguez-Fragoso et al., 2011).
We did not observe any age or, in contrast to our recent study
on the bioavailability of native, micronised and micellar
curcumin (Schiborr et al., 2014), sex differences in the phar-
macokinetics of curcuminoids in the present study. The
observed absence of age and sex differences is in agreement
with data from healthy women and men consuming single
doses of 10 or 12 g native curcumin, although that trial may
have been too small to detect such differences (Vareed et al.,
2008). The sex differences observed in our previous trial on
curcumin pharmacokinetics are probably due to the higher
curcuminoid dose per kg bodyweight ingested by the women
(Schiborr et al., 2014). Thus, the extent of the dose differ-
ences between genders was smaller in the present than the
previous study (500 vs. 98 mg curcuminoids per individual in
the previous and present study, respectively) (Schiborr et al.,
2014).
In the present study, the consumption of a single oral dose
of 80 mg curcumin (98 mg curcuminoids) in its native form or
as micelles, alone or in combination with phytochemicals
(sesamin, ferulic acid, naringenin, xanthohumol), was safe and
well tolerated (Supplementary data).All safety parameters other
than bilirubin in young and aged men, cholesterol in aged
women and men, LDL cholesterol in aged men and cystatin
C in aged men remained within the reference ranges and,
except for cystatin C, were already elevated prior to curcumin
administration and the effect thus independent of curcumin
consumption. The safety of native curcumin, even when in-
gested in gram doses for months, as well as of a single oral
dose of 500mgmicellar curcuminoids in previous studies (Baum
Table 3 – Mean (±SEM) 24 h-urine excretion [nmol/g creatinine] of curcumin, DMC and BDMC in healthy young and aged
women and men after a single oral dose of 98 mg curcuminoids in the form of native curcumin (NC), native curcumin
plus phytochemicals (sesamin, ferulic acid, naringenin, xanthohumol; NCP), micellar curcumin (MC) or micellar
curcumin plus phytochemicals (MCP).1,2
Curcumin NC NCP MC MCP P <
All (n = 23) 1.6 ± 2.8a 16.5 ± 11.0a 437.2 ± 282.2b 315.9 ± 137.5b 0.05
Women young (n = 6) 1.8 ± 2.9a 21.4 ± 17.3a 507.3 ± 373.2b 376.3 ± 97.3b 0.05
Women aged (n = 5) 2.7 ± 5.3a 16.3 ± 10.4a 488.8 ± 369.9b 328.5 ± 180.3a,b 0.01
Men young (n = 6) 1.9 ± 2.5a 12.3 ± 6.1a 250.9 ± 78.0b 212.5 ± 111.9b 0.001
Men aged (n = 6) 1.9 ± 4.1a 15.6 ± 6.2a 463.6 ± 210.9b 331.8 ± 125.2b 0.001
P for group ns ns ns ns ns
DMC NC NCP MC MCP P <
All (n = 23) 1.8 ± 2.2a 16.4 ± 10.8a 146.1 ± 94.5b 104.7 ± 54.3b 0.01
Women young (n = 6) 1.2 ± 1.9a 21.4 ± 17.3a,b 187.8 ± 129.8c 130.2 ± 55.0b,c 0.05
Women aged (n = 5) 1.4 ± 2.1a 16.3 ± 10.4a,b 152.4 ± 105.4c 105.4 ± 57.9b,c 0.05
Men young (n = 6) 1.9 ± 2.4a 12.3 ± 6.1a 99.7 ± 47.9b 69.3 ± 44.6b 0.05
Men aged (n = 6) 2.4 ± 2.8a 15.6 ± 6.2a 145.5 ± 80.8b 114.1 ± 53.8b 0.01
P for group ns ns ns ns
BDMC NC NCP MC MCP P <
All (n = 23) 0.2 ± 0.2a 2.3 ± 1.5a 7.8 ± 4.1b 5.1 ± 2.4b 0.01
Women young (n = 6) 0.2 ± 0.2a 4.0 ± 1.5a,c,A 10.2 ± 4.1b 6.2 ± 1.6c 0.05
Women aged (n = 5) 0.4 ± 0.3a 1.5 ± 0.7a,B 7.6 ± 2.4b 4.9 ± 2.2b 0.05
Men young (n = 6) 0.3 ± 0.2a 1.9 ± 1.4a,B 7.4 ± 5.3b 3.4 ± 2.0a,b 0.05
Men aged (n = 6) 0.1 ± 0.1a 1.6 ± 0.8a,B 6.0 ± 3.4b 5.7 ± 3.0b 0.05
P for group ns 0.05 ns ns
1 Repeated-measure, one-way ANOVA was performed using GraphPad Prism version 5.00 forWindows (GraphPad Software, San Diego, CA, USA)
to analyse differences between formulations, one-way ANOVA was used to analyse differences between groups.
2 Values within a line not sharing a common lower case letter and values within a column not sharing a common capital letter are signifi-
cantly different at the given P-value.
189j o u rna l o f f un c t i ona l f o od s 1 4 ( 2 0 1 5 ) 1 8 3 – 1 9 1
et al., 2007; Carroll et al., 2011; Dhillon et al., 2008; Schiborr et al.,
2014), is in agreement with the present observations.
5. Conclusions
The micellar formulation in this work improved the oral
bioavailability of 80 mg curcumin in healthy humans sign-
ificantly (88-fold). The simultaneous administration of
phytochemicals enhanced the bioavailability of native curcumin
moderately (8-fold), but did not synergistically enhance the
oral bioavailability of micellar curcumin. Both the micellar
curcuminoidsand theco-administrationwith thephytochemicals
sesamin, ferulic acid, naringenin and xanthohumol were safe
and well tolerated and may thus be useful in the prevention or
treatment of inflammatory diseases.
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